TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

39 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • Obesity / overweight

    Weight Loss Study: Genetics and Response to Naltrexone/Bupropion

    Testing whether obesity genes predict weight loss from a diet and a medicine

    📍 Columbia University Medical Center · New York, NY · Get directions →

    The goal of this clinical trial is to understand if genetic variations are associated with the amount of weight loss with diet and while taking an FDA-approved medication for weight loss. The main question\[s\] it aims to answer are: * In Aim One, the investigators propose to rigorously test the hypothesis that presence of the Taq1A A1+ polymorphism is associated with greater weight loss with NB compared with the A1- genotype.

    ✓ Study care freePhase 4Ages 18–65Learn more →
  • Kidney disease

    Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD

    Testing whether empagliflozin changes kidney filter injury proteins in African American Veterans

    📍 Washington DC Veterans Affairs Medical Center (688) · Washington D.C., DC · Get directions →

    Primary Objective:To study podocyte specific injury markers in African American Veterans with non-diabetic kidney disease(NDKD), on empagliflozin therapy. Primary Endpoint: Assess the effect of Empagliflozin on podocyte-specific proteins in exosomes isolated from subjects' urine, such as nephrin, podocalyxin and Wilms'Tumor (WT-1) protein.

    ✓ Study care freePhase 4Ages 19–90Learn more →
  • Obesity / overweight

    Pharmacotherapy in Conjunction With Lifestyle Counseling for Management of Weight Regain After Bariatric Surgery

    Testing medicines plus lifestyle counseling to manage weight regain after bariatric surgery

    📍 University of California Irvine Medical Center · Orange, CA · Get directions →

    This is a randomized controlled trial employing a Sequential Multiple Assignment Randomized Trial (SMART) design to test whether pharmacotherapy, in conjunction with lifestyle counseling, can reverse weight regain after bariatric surgery.

    ✓ Study care freePhase 4Ages 18–70Learn more →
  • Kidney disease

    Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease

    Testing kidney disease drug effects and safety in teens with early CKD

    💵 May compensate

    📍 Instituto de atención Integral de Enfermedades Renales del Estado de Aguascalientes · Aguascalientes, Aguascalientes · Get directions →

    Chronic kidney disease (CKD) is highly prevalent in the state of Aguascalientes, Mexico, particularly among adolescents and young adults. Epidemiologic and histologic studies suggest that this burden is largely driven by reduced nephron endowment of prenatal origin, leading to compensatory glomerular hyperfiltration, adaptive podocytopathy, and persistent albuminuria at early stages of disease.

    ✓ Study care freePhase 4Ages 14–18Learn more →
  • Obesity / overweight

    Effect of Lidocaine-Dexmedetomidine on Pain, Inflammation, and Oxidative Stress After Bariatric Surgery.

    Testing if an IV medicine during bariatric surgery reduces pain and inflammation in adults with

    📍 Hospital de Especialidades Centro Medico Nacional Siglo XXI · Mexico City, Mexico City · Get directions →

    The goal of this randomized clinical trial is to find out whether giving an intravenous lidocaine + dexmedetomidine combination (LIDEX) during laparoscopic bariatric surgery can lower post-operative pain, inflammation, and oxidative stress in adults with obesity. The main questions it aims to answer are: * Pain control: Does LIDEX reduce pain 24 hours after surgery, as measured with the International Pain Outcomes Questionnaire (IPOQ)?

    ✓ Study care freePhase 4Ages 18–60Learn more →
  • Obesity / overweightHigh blood pressure

    Impact GLP-1 Agonists Following Bariatric

    Testing whether GLP-1 medicines after bariatric surgery affect weight and blood sugar

    📍 University of Missouri Hospital · Columbia, MO · Get directions →

    Glucagon-like peptide 1 (GLP-1) is a hormone that helps regulate blood glucose levels through improved insulin sensitivity and release of insulin from the pancreas, control hunger, induce satiety and plays a role in the metabolic health of a person. GLP-1 receptor agonists (GLP1-RAs) have been shown to be effective in achieving weight loss in patients with type 2 diabetes while improving blood glucose control.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Kidney disease

    Randomised Evaluation of Sodium Dialysate Levels on Vascular Events

    Testing whether two dialysate salt levels affect heart events and death

    📍 Royal Adelaide Hospital · Adelaide, · Get directions →

    This global study will assess the effect of randomising dialysis sites to one of two default dialysate sodium concentrations in current practice, 140mmol/l and 137mmol/l, on major cardiovascular events and death in patients receiving maintenance haemodialysis.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Obesity / overweight

    Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors

    Testing a weekly shot to see if it is practical and helps weight in some postmenopausal breast

    📍 Weill Cornell Medicine · New York, NY · Get directions →

    This study will explore whether tirzepatide is a practical and acceptable treatment for postmenopausal females with a history of hormone receptor-positive breast cancer and obesity. The investigators aim to understand whether participants are willing and able to take this medication once weekly for 6 months and whether it may help improve weight and overall health.

    ✓ Study care freePhase 4Ages 18+WomenLearn more →
  • Dementia / Alzheimer's

    Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease

    Studying whether ovarian hormones are linked to aging and Alzheimer’s risk in women

    📍 Mayo Clinic · Jacksonville, FL · +1 more US site · Get directions →

    The researchers are trying to determine whether ovarian hormones are associated with aging processes and with the risk of developing Alzheimer's disease in women.

    ✓ Study care freePhase 4Ages 60+WomenLearn more →
  • Type 2 diabetesKidney disease

    Mechanism of SGLT2 Inhibition in the Kidney

    Testing how SGLT2 medicines affect kidney function in type 2 diabetes

    💵 May compensate

    📍 University of Michigan · Ann Arbor, MI · Get directions →

    The goal of this open-label, non-randomized clinical trial is to determine what effects, if any, an FDA-approved drug class known as SGLT2 inhibitors (Canagliflozin or INVOKANA) has any protective effects on kidney function in Type 2 diabetes. We are looking for participants 18-80 years of age, who have had a clinical diagnosis of Type 2 diabetes for ≥ 3 years.

    ✓ Study care freePhase 4Ages 18–80Learn more →
  • Obesity / overweight

    📍 Medical Dermatology Specialists · Phoenix, AZ · +39 more US sites · Get directions →

    The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Obesity / overweightFatty liver disease (NASH/MASH)

    Fibrosis Lessens After Metabolic Surgery

    Testing whether metabolic surgery can reduce liver scarring in obesity

    💵 May compensate

    📍 Banner Health Center · Phoenix, AZ · +3 more US sites · Get directions →

    Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity, diabetes, and dyslipidemia. MASLD is currently the most common cause of chronic liver disease affecting about 80% of people with obesity, ranging from simple fat deposits in the liver to Metabolic Dysfunction-Associated Steatohepatitis (MASH), cellular injury, advanced fibrosis, cirrhosis, or hepatocellular carcinoma.

    ✓ Study care freePhase 4Ages 18–75Learn more →
  • DepressionDementia / Alzheimer's

    Aβ Dynamics in LLMD

    Testing how treating depression may change brain markers linked to Alzheimer’s

    📍 NYU Langone Health · New York, NY · +1 more US site · Get directions →

    This study will examine the biological factors that may modulate the relationship between depression and the development of Alzheimer's disease (AD). Since the direction of causation between depression and the biological factors associated with AD is unknown, the only way to understand cause and associated risk is to treat the depressive symptoms and examine the effects on AD biomarkers.

    ✓ Study care freePhase 4Ages 60+Learn more →
  • Obesity / overweightHigh blood pressure

    Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease

    Testing treatments to lower high pressure in liver veins in people with advanced liver disease and

    💵 May compensate

    📍 Cleveland Clinic Main Campus · Cleveland, OH · Get directions →

    Cirrhosis is a form of advanced liver disease that can lead to serious complications, especially when combined with severe obesity. Many patients with cirrhosis also develop a condition called clinically significant portal hypertension (CSPH), which is increased pressure in the veins of the liver.

    ✓ Study care freePhase 4Ages 18–70Learn more →
  • Dementia / Alzheimer's

    A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)

    Testing the safety and side effects of Zunveyl in people with mild to moderate Alzheimer’s

    📍 Tekton Research Saint Louis Psychiatry · St Louis, MO · Get directions →

    The primary purpose of this study is to evaluate the safety and tolerability of Zunveyl® over 12 weeks of routine clinical use in adults with mild to moderate Alzheimer's disease.

    ✓ Study care freePhase 4Ages 50+Learn more →
  • Obesity / overweight

    GLP-1R Actions on Muscle and the Skeleton

    Studying how GLP-1 weight loss affects muscles and bones in people with obesity

    📍 Pennington Biomedical Research Center · Baton Rouge, LA · Get directions →

    The GRAMS study objectives are to assess the musculoskeletal changes that occur after weight loss using GLP-1 based therapy. A lifestyle intervention with diet and exercise is included to assess any mitigating effects are provided, versus a control group with regular exercise and diet.

    ✓ Study care freePhase 4Ages 18–50Learn more →
  • Obesity / overweight

    Metabolic and Behavioural Effects of CONTRAVE as Potential Mechanisms of Weight Loss in Adults With Obesity

    Testing how CONTRAVE affects body and behavior changes linked to weight loss in adults with obesity

    📍 LEAF Weight Managment Clinic · Ottawa, Ontario · Get directions →

    Obesity is a common chronic disease linked with increased risk for other illnesses and earlier death. Our team and others have shown that many bodily and psychological changes occur when individuals are on calorie-restricted diets.

    ✓ Study care freePhase 4Ages 18–64Learn more →
  • Kidney disease

    Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis

    Testing whether a weekly diabetes medicine is safe for people on dialysis

    📍 Unity Health Toronto · Toronto, Ontario · Get directions →

    This study aims to determine if GLP1RA is safe and tolerable in maintenance dialysis population, adherence, and feasibility of a larger definitive cardiovascular outcome trial in this population. Participants will be randomized 1:1 to either weekly subcutaneous semaglutide versus usual care and followed for 26 weeks.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Obesity / overweightKidney disease

    Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2

    Studying weight-loss support for people with obesity and kidney disease who want a kidney transplant

    📍 London Health Sciences Centre · London, Ontario · Get directions →

    OK-TRANSPLANT 2 is a vanguard study for a large randomized, pragmatic, open-label trial. We will randomize participants with obesity, high-risk CKD/dialysis who are hoping for lose weight for the purpose of kidney transplant.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Obesity / overweight

    JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity

    Testing how weight-loss lifestyle changes affect metabolism in teens with obesity, with or without

    📍 McMaster University · Hamilton, Ontario · Get directions →

    The Joule MARS study is a single center, randomized, open label clinical trial aiming to explore the metabolic adaptations that occur in response to weight management in adolescents with obesity. Behavioural lifestyle intervention with and without a pharmacological intervention - semaglutide- will be studied.

    ✓ Study care freePhase 4Ages 12–17Learn more →
  • Dementia / Alzheimer's

    Lemborexant for Insomnia in a Patient With Dementia: An N-of-1 Trial

    Testing a sleep medicine for insomnia symptoms in a person with dementia

    📍 Nova Scotia Health · Halifax, Nova Scotia · Get directions →

    Insomnia is a highly common, chronic disorder that is distressful for the patient but also for caregivers and can give rise to a heavy burden on the healthcare team. Sleeping aids like benzodiazepines and other sedatives (e.g., zolpidem, zopiclone) have been widely used to help treat insomnia.

    ✓ Study care freePhase 4Learn more →
  • Obesity / overweight

    Improving Efficacity of Sleeve Gastrectomy With Naltrexone/Bupropion Extended-release Tablet

    Testing whether naltrexone and bupropion tablets after sleeve

    📍 Criucpq-Ul · Québec, Quebec · Get directions →

    The goal of this clinical trial is to assess the impact of combination therapy with Naltrexone-Bupropion (NB) in the post-operative period of sleeve gastrectomy (SG). on a) weight loss, b) resolution of comorbidities and c) eating behaviors.

    ✓ Study care freePhase 4Ages 18–65Learn more →
  • Obesity / overweight

    Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder

    Testing how to choose weight-loss medicines for people with bipolar disorder

    💵 May compensate

    📍 Mayo Clinic · Rochester, MN · Get directions →

    The goal of this clinical trial is to identify the specific characteristics (phenotypes) that may be useful to help select the right medication for weight loss, and to study the effect of individualized guided medication in patients with bipolar disorder ages 18-65. The main questions it aims to answer are: * Can the investigators compare the distribution of obesity characteristics (hungry brain, hungry gut, emotional hunger) between bipolar patients and non-bipolar participants (comparing from IRB #24-002375)?

    ✓ Study care freePhase 4Ages 18–65Learn more →
  • Obesity / overweight

    The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity

    Testing tirzepatide for hot flashes in post-menopausal women with obesity

    📍 Mayo Clinic in Florida · Jacksonville, FL · Get directions →

    The purpose of this study is to determine the effect of tirzepatide on vasomotor symptoms and on measures of biological aging.

    ✓ Study care freePhase 4Ages 46–60WomenLearn more →
  • Obesity / overweight

    2024 Tirzepatide-Bariatric Surgery

    Testing whether taking tirzepatide before bariatric surgery helps outcomes for people with obesity

    📍 University of Kentucky · Lexington, KY · Get directions →

    This clinical trial will test whether preoperative tirzepatide treatment improves outcomes after bariatric surgery. The outcome of this study could impact therapeutic guidelines for the multimodal treatment of obesity.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Dementia / Alzheimer'sParkinson's disease

    Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia

    Studying how nerve cell loss affects thinking ups and downs in Lewy body dementia

    📍 Virginia Commonwealth University · Richmond, VA · Get directions →

    The proposed study aims to address the critical gaps in understanding the mechanisms of CF (Cognitive Fluctuations) by leveraging recently emerged molecular biomarkers, advanced neuroimaging techniques to assess measures of cholinergic degeneration, and synchronous EEG and assessments of attention. One of the overarching innovations of study is combining all of these assessments into one integrated research plan

    ✓ Study care freePhase 4Ages 50–89Learn more →
  • Obesity / overweight

    Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis

    Testing oral semaglutide plus psoriasis skin creams to see effects on symptoms and inflammation

    📍 Hospital Universitario Dr. José E. González · Monterrey, N.L. · Get directions →

    This study will evaluate the effects of oral semaglutide in combination with topical corticosteroid/calcipotriol on clinical outcomes and metabolic inflammation in patients with plaque psoriasis and overweight/obesity and/or type 2 diabetes mellitus. A total of 62 participants will be randomized to receive either semaglutide plus topical corticosteroid/calcipotriol or placebo plus topical corticosteroid/calcipotriol for 12 weeks.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Obesity / overweightType 2 diabetesHeart / cardiovascular disease

    Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants

    Testing the diabetes medicine pioglitazone in people with type 2 diabetes, obesity, and heart

    📍 Texas Diabetes Institute/UH · San Antonio, TX · Get directions →

    Our goal of the study is to learn the effects of the diabetes medication named Pioglitazone, in type-2 diabetic obese participants with Heart failure. The main question it aims to answer are: 1.

    ✓ Study care freePhase 4Ages 30–70Learn more →
  • Kidney disease

    Empagliflozin Treatment in Kidney Transplant Recipients

    Testing empagliflozin in people with kidney transplants and chronic kidney disease

    📍 Edward Hines Jr. VA Hospital, Hines, IL · Hines, IL · +4 more US sites · Get directions →

    Kidney transplantation improves the health and quality of life for those Veterans with end stage kidney disease (ESKD). While early patient and graft survival are excellent, long-term outcomes continue to be challenging.

    ✓ Study care freePhase 4Ages 19+Learn more →
  • Dementia / Alzheimer's

    Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease

    Studying nighttime agitation and restless legs in people with Alzheimer’s

    📍 The University of Texas at Austin · Austin, TX · Get directions →

    Nighttime agitation in persons with Alzheimer's disease causes patient suffering, distresses caregivers, and often results in prescriptions for harmful antipsychotics. Effective treatments are lacking because of limited knowledge of the etiology of nighttime agitation.

    ✓ Study care freePhase 4Ages 55+Learn more →
  • Kidney disease

    Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

    Testing whether pioglitazone can reduce overactive nerve activity in people with chronic kidney

    📍 University of Texas at Arlington · Arlington, TX · +1 more US site · Get directions →

    Chronic kidney disease (CKD) is associated with a higher risk of cardiovascular disease and death. An overactive sympathetic nervous system in CKD patients is one of the major mechanisms increasing the cardiovascular risks in this patient population.

    ✓ Study care freePhase 4Ages 35–70Learn more →
  • Kidney disease

    Oral Iron in Children With Chronic Kidney Disease

    Testing oral iron in children with chronic kidney disease and mild anemia

    📍 Weill Cornell Medicine / New York Presbyterian Hospital · New York, NY · +1 more US site · Get directions →

    This is a pilot clinical trial of oral iron therapy in children with chronic kidney disease (CKD) and mild anemia. Eligible children will be randomized into a standard of care (iron sulfate) arm vs.

    ✓ Study care freePhase 4Ages 1–21Learn more →
  • Heart / cardiovascular diseaseDementia / Alzheimer's

    Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults

    Testing whether lowering cholesterol in older adults affects heart and memory outcomes

    📍 University of Alabama at Birmingham · Birmingham, AL · +37 more US sites · Get directions →

    PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo.

    ✓ Study care freePhase 4Ages 75+Learn more →
  • Obesity / overweight

    The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics

    Testing whether two drugs for bladder and erections affect blood sugar in people with prediabetes

    📍 University of Kentucky · Lexington, KY · Get directions →

    The investigator hypothesizes that treatment with the ß3 agonist mirabegron results in improved glucose metabolism, including a reversal of prediabetes in obese, insulin-resistant human research participants, and this is further improved by combination therapy with tadalafil. The investigator will comprehensively analyze glucose homeostasis in prediabetic patients treated for 14 weeks with mirabegron, tadalafil or both drugs as compared to a placebo.

    ✓ Study care freePhase 4Ages 35–65Learn more →
  • Dementia / Alzheimer'sParkinson's disease

    Comparing Antipsychotic Medications in LBD Over Time

    Comparing medicines to see which works better for hallucinations or delusions in Lewy body disease

    📍 University Health System · San Antonio, TX · +1 more US site · Get directions →

    The primary objective of this study is to determine whether treatment with pimavanserin or quetiapine is associated with a greater improvement in psychosis when used in a routine clinical setting to treat hallucinations and/or delusions due to Parkinson's disease (PD) or dementia with Lewy bodies (DLB) - collectively referred to as Lewy body disease (LBD).

    ✓ Study care freePhase 4Learn more →
  • Obesity / overweight

    Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability

    Testing metformin for weight gain caused by antipsychotic drugs in adults with intellectual

    💵 May compensate

    📍 Centre for Addiction and Mental Health · Toronto, Ontario · Get directions →

    People with IDD (intellectual and developmental disability) have very high rates of obesity and die prematurely from cardiometabolic disease. While antipsychotics contribute to this problem, their use is necessary and appropriate in a significant subgroup of individuals with IDD.

    ✓ Study care freePhase 4Ages 16–65Learn more →
  • Kidney disease

    Safety of Short-course of NSAIDs in Pediatric Patients With CKD

    Testing whether short courses of anti-inflammatory pain medicines after surgery raise kidney injury

    📍 Children's Hospital Colorado · Aurora, CO · Get directions →

    The purpose of this study is to determine if non-steroidal anti-inflammatory (NSAID) use in the postoperative setting increases the risk of acute kidney injury (AKI) in pediatric patients with mild-to-moderate chronic kidney disease (CKD). The investigators hypothesize that there is no increased risk.

    ✓ Study care freePhase 4Ages 2–25Learn more →
  • Obesity / overweight

    📍 AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Avondale · Avondale, AZ · +39 more US sites · Get directions →

    The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with active PsA and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Obesity / overweight

    Tirzepatide in PWS, HO and GNSO

    Testing a weight loss medication in young adults with Prader-Willi or hypothalamic obesity

    📍 Children's Minnesota · Saint Paul, MN · +2 more US sites · Get directions →

    This research study is comparing the effectiveness of a weight loss medication called Tirzepatide in young adults with Prader-Willi Syndrome and/or hypothalamic obesity, as compared to young adults with obesity that is unrelated to a genetic syndrome or underlying medical cause. These groups will be given medication for 1 year to see how weight and other health factors are effected by the medication.

    ✓ Study care freePhase 4Ages 18–26Learn more →